

Table 1: Patient background (continued)

		Analysis 1*			Analysis 2		
		Haloperidol (n = 18)	Haloperidol hydroxyzine (n = 22)	P-value	Haloperidol (n = 9)	Haloperidol hydroxyzine (n = 9)	P-value
Direct factor	Opioid use	12 (67%)	13 (59%)	0.747	7 (78%)	4 (44%)	0.335
	Benzodiazepine use	10 (56%)	10 (45%)	0.751	4 (44%)	3 (38%)	1.000
	Steroid use	2 (11%)	3 (14%)	1.000	1 (11%)	0 (0%)	1.000
	Anticholinergic use	2 (11%)	2 (9%)	1.000	0 (0%)	0 (0%)	-
	Antihistamine use	6 (33%)	5 (23%)	0.498	1 (11%)	1 (11%)	1.000
	Dehydration	6 (33%)	7 (32%)	1.000	2 (22%)	4 (44%)	0.620
	Hypoxia	8 (44%)	12 (55%)	0.751	2 (22%)	5 (56%)	0.335
	Infection/fever	15 (83%)	19 (86%)	1.000	8 (89%)	8 (89%)	1.000
	Hypercalcemia	0 (0%)	0 (0%)	1.000	0 (0%)	0 (0%)	-
	Kidney dysfunction* ²						
	GFR $\geq$ 60	3 (17%)	8 (36%)	0.172	3 (38%)	2 (22%)	0.603
	GFR $\geq$ 30 < 60	6 (33%)	7 (32%)		3 (38%)	3 (38%)	
	GFR < 30	7 (39%)	5 (23%)		2 (22%)	3 (38%)	
	Dialysis	2 (11%)	2 (9%)		1 (11%)	1 (11%)	
	Liver dysfunction	4 (22%)	6 (27%)	1.000	2 (22%)	1 (11%)	1.000
	Brain metastasis	0 (0%)	0 (0%)	1.000	0 (0%)	0 (0%)	-
	Hypoalbuminemia	14 (78%)	20 (91%)	0.381	8 (89%)	8 (89%)	1.000

GFR: glomerular filtration rate

*2: Cochran–Armitage Test